placebo to match baricitinib 4mg and 2mg in appearance clinical trials

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of Baricitinib as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects with New-Onset Polymyalgia Rheumatica (JAK-SPARE 1)

This study is looking at a new treatment called Olumiant for polymyalgia rheumatica. It aims to see if Olumiant can help people get better and reduce their need for steroid medications, which often have side effects. Researchers are checking how well it works and if it's safe.